REGN – Bullish Engulfing + RSI Divergence at Weekly DemandRegeneron (REGN) is showing strong technical signals of potential reversal from a key weekly demand zone, replicating a setup similar to March 2021.
🔹 Bullish Engulfing Candle forms directly at the demand zone after a multi-month downtrend.
🔹 Volume Spike confirms strong buyer interest.
🔹 RSI shows
13,625.00
0.00 BRL
23.79 B BRL
76.56 B BRL
About Regeneron Pharmaceuticals, Inc.
Sector
Industry
CEO
Leonard S. Schleifer
Website
Headquarters
Tarrytown
Founded
1988
ISIN
BRREGNBDR005
FIGI
BBG00P14K7Y9
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Regeneron Pharmaceutical's MFI implying "Trough in the making"1/ Using just this indicator " Alon" is a very dangerous game like you can blow up your
account !!!
2/Non the less, such readings accompanied by (-86%) or ( 78-%) or (-91%) draw downs
such as on the chart above has resulted in the past, in 3 occasions, in big and historical
bullish moves !!! "Gener
Regeneron Pharmaceuticals Q2-Q3 Confirmed "Troughing in ProgressIF we do not crash like many Elliottsions are suggesting implying of Grand 5th wave since 1929...
iF we do not start WW3...
IF everything utterly absolute out there in the pharmaceutical industries locally
and globally...
IF our studies of the relation between XLV and Regeneron Pharmaceuticals is
r
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-t
REGN | Regeneron Pharmaceuticals – Macro Reaccumulation SetupPublished by WaverVanir International LLC | 06/12/2025
Regeneron has completed a deep retracement, touching the 0.886 Fibonacci level (~$567) and entering a strong discount zone, coinciding with a weak low sweep and increasing volume — suggesting potential accumulation by institutions.
🔍 Key Confl
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
7.59%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
5.11%
Maturity date
Sep 15, 2030
See all REGN34 bonds
Curated watchlists where REGN34 is featured.